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for the development of a post transplant cardiac complication. In
patients who suffered a cardiac complication 38% went onto re-
quire intensive supportive care and this was associated with signif-
icant morbidity. Consideration to add medical prophylaxis in pa-
tients with a risk to develop cardiac complications should be
considered in this high risk group.
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PALIFERMIN REDUCES THE INCIDENCE OF ORAL MUCOSITIS AFTER
ABLATIVE PREPARATIVE REGIMENS IN PATIENTS UNDERGOING AN
UMBILICAL CORD BLOOD TRANSPLANT
Rodriguez, T.E.1, Toor, A.A.1, Smith, S.E.1, Parthasarathy, M.1,
Stiff, P.J.1 1Bone Marrow Transplant Program, Department of Medi-
cine, Loyola University Chicago, Maywood, IL.
Oral mucositis (OM) is a major cause of morbidity after myeloa-
blative stem cell transplants. Palifermin has shown efﬁcacy in the
prevention of myeloablative therapy-induced OM in patients un-
dergoing autotransplants for hematologic malignancies. We ana-
lyzed data from recipients of umbilical cord blood transplantation
(UCBT) who received palifermin as prophylaxis for OM both
before and after an ablative preparative regimen. Methods: We
identiﬁed 26 UCBT patients at our institution who underwent the
procedure from May 2003 to August 2006. The ﬁrst 15 patients did
not receive palifermin while the most recent 11 patients received
palifermin at a mean total dose of 150 g/kg over 2 consecutive
days, starting 2 days before the initiation of the preparative regi-
men and 2 days after infusion of the UCB cells starting on day 0.
Patient Characteristics: The median age for the patients in the
palifermin vs. non-palifermin groups was 50 (33-58) and 43 (23-56)
years. The preparative regimens used for the palifermin group
consisted of total body irradiation and cyclophosphamide (TBI/
Cy) in 9/11 patients, and BCNU, etoposide, cytarabine and mel-
phalan (BEAM) in 2/11 patients, while in the non-palifermin
group, TBI/CY was used in 7/15 patients, BEAM in 5/15 patients,
and 2/15 patients received busulfan and cyclophosphamide. The
median post-thaw nucleated cell dose for the palifermin vs. non-
palifermin groups was 1.4 and 1.7  107/kg. Results: Mucositis
occurred less frequently (2/11 vs. 12/15; P  0.004, Fisher’s exact
test) and appeared to be less severe in the palifermin treated group
who also did not have a higher incidence of severe acute graft vs.
host disease. No difference was observed in neutrophil (19 vs. 16
days for palifermin vs. non-palifermin) and platelet engraftment
(57 and 51 days respectively) between the groups. Days of fevers
were less frequent in the palifermin group compared to the non-
palifermin group ( median of 1 day vs. 4 days respectively). Median
days of total parenteral nutrition (TPN) was 0 in the palifermin
group vs. 13 days in the non-palifermin group. Conclusion: Pali-
fermin reduces the incidence of OM and the need for TPN but
does not appear to increase the incidence of severe acute GVHD in
recipients of UCBT transplants after myeloablative therapy.
Grade of Mucositis and Acute GVHD With or Without Palifermin
in Umbilical Cord Blood Transplant Patients.
Treatment
Group No.
Mucositis
Grade 0
Mucositis
Grade 1-2
Mucositis
Grade 3-4
GVHD
Grade 0-I
GVHD
Grade
II-IV
GVHD
Grade
III-IV
Palifermin 11 9 1 1 10 1 1
Non-
Palifermin 15 3 9 3 3 7 2
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AMD 3100 SUCCESSFULLY MOBILIZES AUTOLOGOUS CD34 CELLS
AFTER FAILURE OF G-CSF MOBILIZATION REGIMENS WITH LOW TOX-
ICITY AND ACCEPTABLE AUTOLOGOUS STEM CELL TRANSPLANT
(ASCT) OUTCOMES
Shaughnessy, P.J.1, Hougham, M.1, Bachier, C.1, LeMaistre, C.F.1
1Texas Transplant Institute, San Antonio, TX.
AMD3100 reversibly inhibits SDF-1alpha/CXCR4 binding and
induces rapid mobilization of CD34 cells into the circulation
which can potentiate stem cell mobilization by G-CSF alone. We
report our institutional experience using AMD3100, as part of a
larger compassionate use protocol, in patients (pts) who failed to
collect 2 million CD34 cells/kg using standard methods of au-
tologous peripheral blood stem cell mobilization (PBSCM).
Twelve pts (male n6, median age 65 years [range 32-73]) with
non Hodgkins lymphoma (n6), multiple myeloma (n4), and
Hodgkins disease (n2) were treated on study. All pts had failed a
median of 1 prior PBSCM (range 1-3) with chemotherapy followed
by G-CSF(n9) or G-CSF alone (n6). Study treatment was
neupogen 10ug/kg daily in the AM and AMD 3100 240ug/kg
beginning day 4 at 2200. Apheresis of a 3 blood volume exchange
began day ﬁve, 10 hours after the ﬁrst AMD 3100 injection and 1
hour after the daily AM neupogen injection. This schedule con-
tinued daily until adequate CD34 cells were collected or the pts
were taken off study. Eleven (92%) pts mobilized adequate
CD34 cells to proceed with high dose chemotherapy and ASCT.
A median of 2.1 million/kg CD34 cells (range 1.1 to 5.5) were
collected in a median of 3 (range 1-4) apheresis days. The maxi-
mum median peripheral blood CD34 cell count prior to study
was 8 cells/ul (range 1-25) but after administration of AMD3100
increased to 22 cells/ul (range 14-160) (p0.03). Six pts reported
mild reversible adverse events (AEs) possibly related to AMD3100,
and no severe AEs were attributed to study drug. Nine pts pro-
ceeded to high dose chemotherapy and ASCT, 2 pts are pending
start of ASCT, and one pt had insufﬁcient CD34 cells for ASCT.
Eight pts are evaluable for engraftment with a median day to ANC
greater than 500/ul of 12 days (range 11 to 15) and platelets greater
than 20 K/ul of 20 days (range 14 to 39). There was no transplant
related mortality at day 100 or unexpected transplant related tox-
icity. Two of 12 pts have died, both from relapsed disease 6 months
post ASCT. A cohort of 60 pts underwent standard PBSCM and
ASCT during the same time period as the study pts and the groups
will be compared for differences in ASCT outcome and supportive
care needs. In conclusion, this single institution case series of pts
demonstrates that AMD3100 can mobilize signiﬁcantly more
CD34 cells in pts who have failed standard PBSCM, with little
toxicity and acceptable ASCT outcomes.
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EVALUATION OF SINGLE-DOSE PALIFERMIN TO REDUCE MUCOSITIS:
ASSESSMENT OF EFFICACY AND SAFETY IN PATIENTS (PTS) WITH
HEMATOLOGIC MALIGNANCIES (HM) RECEIVING AUTOLOGOUS PE-
RIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANTATION
Shea, T.1, Kewalramani, T.2, Mun, Y.3, Jayne, J.3, Dreiling, L.3
1University of North Carolina, Chapel Hill, NC; 2Memorial Sloan
Kettering Cancer Center, NY, NY; 3Amgen Inc., Thousand Oaks, CA.
Palifermin has been approved for pts with HM undergoing
PBPC transplantation with a regimen of 3 daily doses of 60 g/kg
pre- and post-myeloablative conditioning. The pre-dosing may,
however, be inconvenient for some pts. This study was initially
developed to demonstrate the non-inferiority of 3 collapsed (180
g/kg) pre-dosing schedules in reducing the incidence of severe
oral mucositis (OM) (WHO grade 3 or 4) induced by fractionated
total body irradiation (fTBI) and high dose chemotherapy in pts
with HM undergoing PBPC transplantation. The study was
stopped early due to the decreased utilization of fTBI resulting in
slow accrual. Methods: Pts were 18 to 74 years old with HM, a
Karnofsky performance score70%, and eligible for fTBI (12 Gy)
followed by cyclophosphamide (100 mg/kg) and optional VP-16
(60 mg/kg), with autologous PBPC support. Pts were randomized
(1:1:1:1) to receive the FDA approved palifermin dose and schedule
of 60 g/kg administered once daily for 3 days prior to the start of
fTBI (control, Arm A) versus palifermin 180 g/kg administered
once only on day -1 (Arm B); day -2 (Arm C); or day -3 (Arm D)
prior to the start of fTBI. Pts were stratiﬁed by VP-16 use and the
number of days of fractionated TBI. All pts received palifermin 60
g/kg for 3 days post transplant (days 0, 1, 2). Results: The
incidence of severe OM has been previously reported for the 47
randomized pts (ASH 2006). The incidence of severe OM was 82%
(9/11), 60% (6/10), 31% (4/13), and 75% (9/12) in Arms A, B, C
and D, respectively. Most adverse events (AEs) occurred at fre-
quencies  10% and had a similar incidence across all treatment
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arms. The most frequently observed AEs were diarrhea, nausea,
vomiting, fatigue, and rash. The incidence of rash (40%, 36%,
46%, and 33% for Arms A, B, C, and D respectively) was compa-
rable with the previously reported palifermin AE proﬁle. Overall
summary of AEs is presented in Table 1. Conclusion: The toler-
ability of the palifermin collapsed pre-dose arms is similar to Arm
A, with an incidence of AEs across all arms that is consistent with
the expected palifermin safety proﬁle. These results suggest that a
single pre-dose schedule can be tolerated and is a more convenient
dosing schedule. Timing of palifermin in a collapsed dose admin-
istration regimen may affect the efﬁcacy of OM reduction. This
concept warrants further study.
Overall Summary of Adverse Events
Arm A
(N10)
Arm B
(N11)
Arm C
(N13)
Arm D
(N12)
Pts who had any AEs 9(90%) 10(91%) 12(92%) 12(100%)
Pts who had study drug-
related AEs 5(50%) 5(45%) 6(46%) 5 (42%)
Pts who had serious AEs 1(10%) 3(27%) 4(31%) 1 (8%)
Pts who had serious
study drug-related
AEs 0 (0%) 1 (9%) 0 (0%) 0 (0%)
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LOW DOSE AMBISOME ANTI-FUNGAL PROPHYLAXIS IN PEDIATRIC
ALLOGENEIC UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANT
Shinkle, M.1, Carver, A.1, Quinones, R.1,2, Foreman, N.1,2, Gore, L.1,2,
Peltz, A.1,2, Christensen, M.1,2, Wightman, C.1,2, Kissane, R.2,
Malcolm, J.1, Hild, E.1, Giller, R.1,2 1The Children’s Hospital, Denver,
CO; 2University of Colorado School of Medicine, Denver, CO.
Invasive fungal infections (IFI) are a major cause of morbidity
and mortality following allogeneic hematopoietic stem cell trans-
plant (HSCT). To reduce the rate of IFI, in 1996 we initiated a
program of bi-weekly lipid-based Amphotericin prophylaxis for
patients receiving unrelated HSCT. A total of 76 consecutive
patients received transplants from unrelated donors (Cord, MUD)
between 1/1/1996 and 6/30/2005. Three patients with docu-
mented or suspected pre-HSCT IFI were excluded from analysis
due to ongoing anti-fungal therapy at HSCT. Four patients re-
ceived alternative prophylactic regimens by physician choice. An
additional 3 patients were excluded due to death prior to initiation
of anti-fungal prophylaxis. Thus, a total of 66 patients were
deemed evaluable in this retrospective analysis. Sixty-four received
Ambisome, 3mg/kg/dose twice weekly from day -1 thru day 100
post-HSCT. Two patients received bi-weekly Abelcet prophylaxis
due to Ambisome allergy. Treatment was reduced or held for
elevations of serum creatinine. Additional anti-fungal measures
included HEPA air ﬁltration, intranasal Amphotericin B, oral Clo-
trimazole and Nystatin. Median patient age at HSCT was 7.5 years
(range, 0-24). Indications for HSCT included ALL (33), AML
(13), CML (3), JMML (3), NHL (1), Aplastic Anemia (2), SCID
(2), Metabolic Disorder (5), Other (4). The majority of patients had
unrelated cord blood allografts (59) and received GVH prophylaxis
which included ATG, cyclosporine and steroids. IFI documented
by culture and/or histology during the prophylaxis period occurred
in 9 of 66 evaluable patients (14%). Causative organisms were
Aspergillus fumigatis (3), Aspergillus terreus (1), Candida parap-
sillosis (3), Candida tropicalis (1), Candida glabrata (1), Trichos-
poron (1). Sites of infection included blood (6), lung (4), other (2).
Death due to IFI occurred in 3 of 66 patients (4%). Grade III renal
toxicity occurred in 5 of 66 patients (8%); no grade IV renal
toxicity was seen. We conclude that Ambisome anti-fungal pro-
phylaxis is well tolerated and may reduce morbidity and mortality
due to IFI in high risk HSCT patients.
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N-ACETYLCYSTEINE ADMINISTRATION FOR THE PREVENTION OF THE
LIVER COMPLICATIONS FOLLOWING ALLOGENEIC HEMATAPOETIC
STEM CELL TRANSPLANTATION
Zook, J.1, Triﬁlio, S.1, Scheetz, M.1, Pi, J.1, Golf, M.1, Mehta, J.1
1Northwestern Memorial Hospital, Chicago, IL.
Hepatic complications following allogeneic stem cell transplan-
tation(HSCT) are a source of morbidity and mortality. A correla-
tion exists between bilirubin levels(as a marker) and mortality and
evidence exists that bilirubin itself may be responsible for end-
organ damage. A study of 1400 HSCT patients found that an
increase in bilirubin from 1mg to 3mg regardless of cause(GVHD,
SOS, sepsis,etc.), was associated with a mortality hazards ra-
tio6.4. Mortality for bilirubin  4mg was 50%.(Gooley et al.
Hepatology 2005(41)345). Since correction of highly elevated bil-
irubin levels is seldom successful, early interventions are needed to
prevent toxicity. N-acetylcysteine(NAC) is an anti-oxidant, useful
at reducing stress from reactive oxygen species(ROS). Recipients of
allogeneic HSCT at NMH were initiated on iv NAC 100mg/kg/d
(4 daily doses). Criteria for use included 1) an increase in absolute
bilirubin 2.0 or 2) doubling of baseline bilirubin  1.6. All
patients received ursodiol 300mg po tid. 31 patients who received
NAC therapy for 7days and had complete laboratory data available
were evaluated to determine the efﬁcacy of NAC in preventing
complications of liver disease following allogeneic HSCT. Condi-
tioning regimens included.Busulfan /Fludarabine(n15) Busulfan/
Cytoxan(n3), Cytoxan /- Melphalan( n9), TBI/VP-16( n4).
Median day for initiation of NAC was 9 days post HSCT(range
-4-43). Median bilirubin level prior to NAC therapy was
2.8mg(range1.6-13.7). Response: 24/31(77%)had positive respons-
es(decreased from baseline), while in 7/31(23%) bilirubin increased
during the 7days of treatment.(p.001). Only 2/24 responders had
GVHD, while 5/7 non-respoders had GVHD. (p.0023:Fischers
Exact test). Baseline bilirubin differed between responders and
nonresponders(3.1 and 7.0 respectively:p.0023). Responders im-
proved liver toxicity grade(NCI criteria ) from grade 3 to grade
2(median bilirubin improved from 2.8mg/dl to 1.7mg/dl). 4 re-
sponders whose bilirubin increased after NAC was discontinued,
successfully responded after re-challenge. Overall 100day non-
relapse mortality22%: (Bu/Flu3/15(20%):Bu/CY0/3(0%):
TBI/VP3/4(75%):CY/Mel1/9(11%).
NAC was effective in preventing the upward trend of bilirubin
s/p HSCT, a complication associated with excess mortality. Initi-
ating therapy before bilirubin levels become excessively elevated
may improve successful outcomes. This preliminary data should
encourage future research in prevention of liver toxicity post
HSCT.
NAC therapy results
Conditioning regime n % responders (P)
Busulfan/Cytoxan 3 100
Busulfan/Fludarabine 15 80
TBI/VP-16 4 25
Cytoxan /- Melphalan
(non-myeloablative) 9 91
GVHD 7 28(.0023)
Bilirubin <3.1mg 24 72(.0023)
Bilirubin >7.0mg 7 28(.0023)
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